MOUNTAIN VIEW, Calif., June 15, 2020 (GLOBE NEWSWIRE) — ChemoCentryx, Inc. (Nasdaq: CCXI) announced today the completion of its follow-on offering of 5,200,000 shares of its common stock. ChemoCentryx also announced today that the underwriters of its follow-on offering exercised in full their option to purchase an additional 780,000 shares of common stock. All such shares were sold by ChemoCentryx at the follow-on public offering price of $58.00 per share. The net proceeds to ChemoCentryx from this offering are approximately $325.4 million, after deducting underwriting discounts and commissions and estimated offering costs.
SVB Leerink and Piper Sandler acted as joint lead bookrunning managers for the offering, Canaccord Genuity and Raymond James acted as joint bookrunning managers for the offering and H.C. Wainwright & Co. acted as lead manager for the offering.A registration statement on Form S-3 relating to these securities became effective upon filing with the U.S. Securities and Exchange Commission (SEC) on June 10, 2020. The offering was made only by means of a prospectus supplement and accompanying prospectus, which were filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. These documents may also be obtained from: SVB Leerink LLC, Attn: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6218, or by email at [email protected]; or Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at [email protected].This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.About ChemoCentryx
Bay Street News